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Biostatistical Issues in the Design and
Analysis of Animal Carcinogenicity
Experiments
by ChristopherJ. Portier
Two-year animal carcinogenicity experiments are used to evaluate the potential carcinogenicity from exposure to
chemicals. Thechoiceofexposurelevels, theallocation ofanimalstodoses, thelengthofexposure, andthechoiceofin-
terimsacrificetimesallaffectthepowerofstatistical testsforcarcinogeniceffects andthevarianceofinterpolated estimates
ofcarcinogenicrisk. Inthispaper, oneaspectofthisproblemsisconsidered: theabilityoftumorincidencedatato pro-
videinformationoncarcinogenicmechanismandtheoptimalchoiceofdesignparameterswithwhichtoachievethispur-
pose. Thedirectapplication ofbiochemical data totheestimation ofcarcinogenic riskisalsodiscussed indetail.
Simple Stage Model
Themechanismbywhichchemicals inducecarcinogenic re-
sponseintestanimals canbeanimportantfactorinestimatingthe
potentialcarcinogenicriskresultingfromhumanexposure. The
primarymethodusedbyU.S. regulatoryagencieshasbeentoesti-
matecancerrisksusingdatafrom2-yearanimalexperimentsand
conservative models for estimating low-dose risks. However,
therehasbeenincreasingpressureontheseagenciestousemecha-
nisticmodelsfortheestimationofcarcinogenicrisks. Amongthe
potential models for use, themultistagemodelsofcancer(1-3)
thatincludeclonalexpansionofcellsinthevariousstagesofcar-
cinogenesis have receivedthemostattention. Several authors have
suggestedthe useofonespecific formofthisclassofmodels, a
simple two-stage model ofcarcinogenesis used extensively by
Moolgavkar and co-workers (4,5) and Cohen and co-workers
(6-8).Figure 1 illustratesthismodel.Basically, normalcellsare
transformed(viamutation) intopremalignant orinitiatedcells.
Theseinitiatedcellsproliferateordieoutviaasimplebirth-death
process. They canalsoundergo asecondtransformationthatre-
sults in amalignant celland mayeventually grow into atumor.
Theshapeofthedose-response curveforcarcinogenesishas
asignificantimpact onlow-doseestimatesofcarcinogenic risks.
Modelsforwhichtheslopeofthedose-response curveispositive
and finite at dose zero are referred to as "low-dose linear"
models. Forthesemodels, smallchangesofdoseinthelow-dose
rangewouldresultinproportional increases intheprobability of
cancer. Models for which the slope of the dose-response curve
is zero or negative in the low-dose range are referred to as
"nonlinear" models. Forthesemodels, asmall increase indose
inthelow-dose rangewill resultinalmost nochange intherisk
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ofcancer. Ithasbeenshownthattheusualanimalcarcinogenicity
experiment provides very little information on dose-response
shapeandthatmodelsthatyieldwidelydivergentlow-doserisks
will adequately fitmostdata.
PortierandEdler(9)consideredtheabilityoftumorincidence
datatodifferentiatebetweenvariousmechanismsofcarcinogen-
esiswithinthecontextofthetwo-stagemodel (Fig. 1).Usingsug-
gestionsofothers(10,11),theyclassifiedcarcinogeniceffectsinto
threebasicclassesdependinguponhowthedoseeffectisincor-
poratedintothemodel. "Initiators"aredefinedasthosecarcin-
ogensthataltertherateatwhichcellsmovefromthenormalstate
totheinitiatedstate(a, inFig. 1). "Promoters" arethoughttobe
chemicalsthatactdirectlyonthebirthrateofinitiatedcells((3)by
clonallyexpandingthenumbersofthesecells. Thefinalmecha-
nisticclassusedby PortierandEdlerwaslabeled "completer."
Thesearechemicalsthataffecttherateatwhichinitiatedcellsare
transformedintomalignantcells,thuscompletingthecarcinogen-
icprocess.
Thesemechanistic labelsforcarcinogenicactionarebasically
derivedfromatypeofcarcinogenesisexperimentknownasthe
initiation-promotion-intiation (IPI)experiment. IntheseIPIex-
periments, asingledoseofaninitiatorisgiventothetestanimals
at the start ofthe experiment. This is followed by chronic ex-
posure to a promoter and, after some time, the application of
another initiator. Theorderinwhichthechemicalsaregivenis
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crucialtotherateoftumorformation. Thatis, ifthepromoteris
givenfirst, followedbytheinitiator, veryfew, ifany, tumorsare
formed. ItisthoughtthattheinitiatorinteractswiththeDNAof
normal cellscausingmutationswhichsomehowpredisposethese
mutatedcellstocarcinogenesis. Thepromoteristhoughtto in-
crease the clonal growthofonly the initiated cell, allowing the
numbers ofthesecellstoincreaserapidlyrelativetothenormal
cells. Finally, thesecondinitiator(orcompleter)completesthe
carcinogenic process by causing a second mutation in the in-
itiated cell, which results in the formation oftumors.
Inanattempttoimprovetheestimationoflow-doserisks, ithas
beenproposedthatmechanisticmodelsofcarcinogenesisbeused
in the risk assessment process. The advantage ofmechanistic
models ofcarcinogenesis overmoreempirical models isthatit
is believedthatdifferentcarcinogenicmechanismswillresultin
different dose-response shapes. Fromthe discussionabove, if
this istrue, theninformationonthemechanismofactionofacar-
cinogenic substance will result in improved low-dose risk
estimates. Forexample, itiswidelyheldthatchemicallyinduced
mutationsofthetyperesultingfrominitiatorsandcompletersare
low-doselinear(10,11). Themechanismsthatleadtochemically
inducedpromotionarethoughttobe nonlinear. Thesetheories
are highly speculative (12); yet, we can look at the operating
characteristics ofapplying them to see iffurtherresearch into
their use is warranted on statistical grounds.
Intheiranalysis, PortierandEdler(9) wereableto showthat
theusualdesignoftheanimalcarcinogenesisexperimentprovid-
edlittleinformationthatcouldbeusedtodifferentiatebetween
linearinitiation/completioneffectsandnonlinearpromotionef-
fects. Theirbasicapproach was as follows. Control ratesforthe
baseline (untreated) parameters in the two-stage model were
chosenusinghistoricalinformationonalargepopulationofcon-
trolanimals(13). Variouslevelsofdoseeffects(lowtumoryield
tohightumoryield) weredeterminedforeach setofparameters
foreachpotentialmechanism(initiation, promotion, andcom-
pletion). Given one such hypothesized model, they then sim-
ulatedtheresultsofan animalcarcinogenicityexperimentbas-
ed on a particular choice ofdesign parameters. These design
parametersincludedthestandarddesign(nointerimsacrifices,
threedosed groups andacontrol group, 50animalspergroup,
doses in the relative magnitude of0, 0.25, 0.5 and 1) andeight
otherdesignsthataddedstart/stopdosingandinterimsacrifices.
For each simulated data set, parameters for four two-stage
models (the four two-stage models fit to the data included a
modelwheretheeffectofdosewasaninitiationeffect, amodel
forwhichtheeffectofdosewasacompletioneffect, amodelfor
which the effect ofdose was a promotion effect, and a global
modelwhichallowedforallthreetypesofeffects)wvreestimated
based on maximum likelihood estimation. Likelihood ratio
techniques were used todetermine how often each ofthethree
singular-effectmodels(initiationonly,promotiononly, andcom-
pletiononly)describedthedataaswellasthemodelthatallowed
forallthreeeffects. Underthismodelingscheme,theywerethen
abletostudytheeffectofchangingthedesignofthecarcinogen-
esis experiment onthe rateofrejectionofthevarious models.
Undertheusualdesignofanimalcarcinogenicityexperiments,
it was generally found that all ofthe models fit the data well,
regardlessoftheunderlyingmodel. Whendataweregenerated
assumingalinearinitiation-onlyeffect, theinitiationmodeland
thecompletionmodelprovidedasgoodafitastheglobalmodel
invirtuallyallcases(>99% ofthetime). Allthreemodelswere
accepted in 85-95% of the cases studied (depending on the
magnitudeoftheassumeddoseeffect). Whenalinearcomple-
tion effect was assumed, similar results were obtained. Ifthe
completioneffectwasassumedtobeafunctionofdosesquared
(quadraticcompletionmodel), approximately 98% ofthecases
were adequately fit by either a linear initiation model or a
quadratic completion model and 74-93% ofthe cases studied
were fitby all threemodels.
Forpromotioneffects, PortierandEdler(13)considereddose
effects on thebirth rate ofinitiatedcells that werefunctions of
doseraisedtothefirstpower(linearpromotermodel)upthrough
the fourth power (quartic promoter model), resulting in four
basicmodels. Whentheassumedmodelwasbaseduponalinear
promotioneffect, allthreemodels (linearinitiator, linearcom-
pleter, andlinearpromoter)fitthedatainapproximately95% of
thecases studied. Astheshapeofthedoseeffectbecamemore
nonlinear, itwaspossibletorejectthelinearinitiationmodeland
the linearcompletion model with greaterpower. For a quartic
promotionmodel, theinitiationandcompletionmodelscouldbe
rejectedin 15-50% ofthecasesstudied, whereasthepromotion
modelwasacceptedinabout95% ofthecases. Thus, only fora
highly nonlinearpromotioneffect was there any strong degree
ofdifferentiation between thesemodels when theusual design
ofthe long-term animalcarcinogenicity experiment was used.
Based on these results, Portier and Edler (13) considered
severalalternativedesigns. Whentheunderlyingmodel wasbas-
edonalinearinitiationeffect,therewasaslightimprovementin
theprobabilityofrejectingthepromotionmodel;going from4
to 12% intheusualdesignto5 to26% inthestart-stopdesigns.
The ability to reject the completion model did not change
noticeably when the start-stop designs were used. When the
underlying model was a linear completion model, the results
weresimilartotheinitiationmodel. Foranunderlyingquadratic
completionmodel, itwasmoredifficulttorejectthepromotion
modelandeasiertorejecttheinitiationmodel. However, these
differences were small. Finally, for underlying promotion
models, theuseofstartstudiesreducedthepercentageoftimes
we could reject the initiation model or the completion model
whencompared totheusualbioassaydesign. Thisisduetothe
factthatfewerdoseswereused(infavorofequaldosesovervary-
ing time spans) and thatboth magnitude ofdose and length of
dosing play an important role in differentiating between in-
itiators/completers andpromoters.
Theresultsofthisresearchsuggestthatdifferentiationbetween
initiation andcompletionisbestaccomplished with start-stop
dosing experiments; that the rejection of a promotion model
whenthedoseeffectintheunderlyingmodelisaninitiationef-
fect or a completion effect is improved by using an early
exposure-stopexposuregroupintheexperiment; andthatifthe
underlyingmodelisanonlinearpromotionmodel, itisbetterto
usemultipledosesthanstart-stopdosingatsimilarlevelsofex-
posure. Finally, itwasfoundthatallthedesignsweregenerally
poor fordistinguishing mechanism.
Damage-Fixation Multistage Model
Afterreviewingtheresultsoftheseexperiments, itwasclear
thattumorincidencedatacouldnotbereliablyusedtodetermine
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FIGURE 2. A two-stage model ofcarcinogenesis (damage-fixation multistage
model) that incorporates damage and repair.
how treatment affects mutation rates and birth/death rates in
multistage models ofcarcinogenesis. One way outofthis dilem-
ma is to use othertoxicological data such asthe sizeandnumber
ofinitiated cells (14). However, current research is focusing on
the use ofdirect mechanistic information on the carcinogenici-
ty of a compound to estimate the tumor incidence rate and then
to use thetumorigenesis data fromtheanimal carcinogenicity ex-
periment to validate the model. To be able to do this, a slightly
different model ofcarcinogenesis is needed. It has been noted
that a mutation is itselftheresultofa process that involves atleast
two steps. In the first step, damage must occur. For a mutation
to occur, this damage must then be fixed by replication of the
damaged cell. It is also clear that this damage may not persist
forever but may be repaired via numerous mechanisms in the
cell. Thus, several events are competing or combining to result
in a single mutation. The model presented in Figure 1 does not
explicitly account for this more detailed mutation process.
The model ofcarcinogenesis illustrated in Figure 2 is also a
two-stage model ofcarcinogenesis with clonal expansion ofall
cell types. This model is referred to (15,16) as the damage-
fixation multistage model (DFM). Themodel has five cell types:
normal cells, two types of damaged cells and two types of
mutated cells in which the DNA damage has been fixed by cell
replication. For acell tobecomemalignant, itmust pass from the
normal statethrough eachofthemutational states. Thedynamics
ofthemodel canbe illustrated as follows. Normal cells areallow-
ed todivide anddie ordifferentiate. Normal cellstransform in-
todamaged cells via some type ofgenetic aberration (e.g., for-
mation of DNA adducts, single-strand breaks, chromosomal
translocation). The genetic aberrations in these damaged cells
are assumed to pertain to a single strand and can be repaired,
returning thecell to its normal state. When celldivision occurs
inthese unrepaired cells, the DNA damageis fixedin oneofthe
daughter cells resulting inthecreation ofa single mutated cell.
The other daughter cell is derived from the strand of DNA
without damage and is thus a normal cell. The process of
damage, repair, birth, anddeath is repeated inthe second stage.
The DFMmodel allows forthedirectinclusionofbiochemical
datainto ananalysis ofcarcinogenicmechanism andtheestima-
tion ofcarcinogenic risk. These data include the rate offorma-
tion of DNA adducts (DNA damage), the rate ofDNA repair,
and the rateofcell replicationanddeath. Firstconsider the rate
ofDNA damage. Forexample, ithasbeendemonstratedthatad-
ministration of 3 nmole of 7,12-dimethylbenz[alanthracene
(DMBA) toSwissmiceresults in abindingof 1 nmoleofDMBA
permoleofDNA-P24hrafter exposure. Ifthisdamageiscritical
totheconversion ofnormal cells into first stagecells, thenthese
data can be incorporated into the model directly by setting R
equaltotherateofbindingperunittime(beingcertaintoexpress
thisrateintheproperunitsofrateofdamagepercellperunitof
time). However, it is more likely that some specific type of
damage isinducingthemutation. Inthiscase, therelativechange
inthenonspecificdamageasafunctionofdosecanbeusedasa
surrogate forthe relativechange inthe specific binding. In the
exampleabove, adoseofDMBAof150nmoleresultedinabin-
ding of 14 nmoleofDMBAper moleofDNA-P 24hr afterex-
posure (i.e., a 50-fold increase in dose ofDMBA resulted in a
14-foldincrease inbinding). Thus, eventhoughthespecificad-
ductthatinduces themutation isunknown, a 14-fold increase in
the specific adductwhichinducesthemutationcouldbeassumed
when going from adoseof3 nmole to 150 nmoleofDMBA.
Estimatesofthe repairrates forDNAdamagecanbeobtain-
ed in similar ways. The most obvious method is to directly
measure theactivity ofproteins involved intheDNArepairpro-
cess such as06-alkylguanine-DNA alkyltransferase. However,
likenonspecific versus specific DNAdamage, thespecificrepair
mechanism is generally unknown, andsotheproteins involved
in its repairarealsounknown. Onewaytoavoidthiswouldbeto
obtainthe DNA damageratefrombiochemical experimentsus-
ing simplecompartmentmodelsandestimatetherepairratefrom
data on tumor incidence ordataon thesize distribution ofcells
in each stage. This approach is likely to lead to statistical
dependencies in the estimated parameters and large uncertain-
ty intheestimatedtumordamageatseveraldifferenttimepoints
following exposure. Inthis case, thedifferences overtime inthe
amount ofDNA damage should yield an estimate ofthe repair
rate. This method is preferableto using tumor incidence dataor
cellcountdatabecause theestimateoftherepairratewould come
directly fromdata on DNAdamage andwouldnotbedependent
onthe applicability ofthemodel. A thirdmethod forestimating
DNA repair would be to see how much ofthe damage could be
fixedatdifferenttimes following exposuretothecompound. For
example, in the two-stage experimental protocol described
above, waitingvarying lengths oftimesfrom initiation tothe start
ofpromotion allows for alonger period ofDNA repair and the
level ofDNA repair canbe estimated.
Therearealsoavariety ofways in which cell replication rates
canbemeasured inanimaltissues. Thesemethods arevery direct
inthe sensethat, in afixedperiodoftime, they labelallcellsthat
haveundergone replication. These techniques canevenbe used
withothercellulartechniques suchas staining forenzyme altera-
tion. Inthiscase, itispossibletodirectly measure the rateofcell
replication innormal cells, ininitiatedcells (provided aprobe ex-
ists forstaining thecellsorinsomeotherway labelingthem), and
in malignant cells. The technology for the direct estimation of
celldeath/differentiationratesarecurrentlybeingdeveloped. As
thesebecomeavailable, theycanbedirety incorporated into the
DFM model. Untilthen, information onthe sizedistributionand
numberofinitiated callscanbe used to estimatethis parameter.
Theapproach ofestimating theseparameters from dataother
than tumor incidence data is illustrated in Portier and Kopp-
Schneider (15) and Kopp-Schneider et al. (16).
Discussion
Thispaperhas reviewed someoftheproblems concerning the
characterization ofmechanistic models ofcarcinogenesis using
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tumorigenesisdata. Onstrictlystatisticalterms, itwasshownthat
the usual two-year rodentcarcinogenicity experimentdoes not
provide sufficientinformationtobeabletodifferentiatebetween
somebasic mechanistic modelsofcarcinogenesis. Modification
of the bioassay design to include time-varying doses did not
dramatically improve thisproblem.
Atwo-stagemodelofcarcinogenesis thatallowsforthedirect
inclusionofbiochemicaldataintotheestimationofcarcinogenic
risks was reviewed. This approach has the advantage that the
tumorincidencedatafromthelong-termanimalcarcinogenesis
experimentand/orthecell-kinetic information oncellsinthedif-
ferent stagescanbeusedtovalidate themodel. However, there
arenumerousproblemswiththeuseofthismodelingapproach
for risk estimation. It is imperative that an attempt is made to
validatethemodelpredictions usingtheavailabletoxicological
data (e.g., tumor incidence data from carcinogenicity ex-
periments, papilloma counts from skin painting studies, etc.).
Thisvalidationneeds tobedone withextremecautionbecause
goodness-of-fit tests that would be used in this context are
generally insensitive to moderate changes in the model
parameters orevenslightlydifferentmodels. Notonly arethere
statistical problems with this approach, but there are inade-
quacies inthebiologicaldescriptionofDNAdamageandrepair
intheDFMmodel. TheDNAofacellcanbedamagedinmany
placesinmanydifferentways; itmaybethatcellswithmultiple
DNAdamagearemore(orless) susceptibletoreplicationand/or
mutation than are cells with little DNA damage. The model
presented here assumes that DNA damage is either present or
not, thususingonlypartialinformationconcerningtheprocess.
TherateofDNArepair inany onecell islikely tobetied tothe
amountofdamageinthatonecell, aconceptthatisnotallowed
in the currentmodel formulation. Other issues such as strand-
specific DNA repair, preferential DNA repair, and DNA hot
spots will also limit the usefulness ofmodels ofthis type. Cell
replicationratesmustalsobeappliedcautiously; iftheincreased
cellreplicationonlypertainstoasmallfractionofthetotaltissue,
thismustbeaccountedfor. Finally,alloftheseratesmaychange
with age as well as dose, thus the experiments in which these
biochemicalparametersareobtainedmustincludeseveralages
as well as several doses.
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